These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. Harrington JM; Schwenke DC; Epstein DR; Bailey DE Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236 [TBL] [Abstract][Full Text] [Related]
9. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626 [TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. Shahani S; Braga-Basaria M; Basaria S J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Grossmann M; Zajac JD Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052 [TBL] [Abstract][Full Text] [Related]
12. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Lage MJ; Barber BL; Markus RA Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Collier A; Ghosh S; McGlynn B; Hollins G Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430 [TBL] [Abstract][Full Text] [Related]
14. Metabolic complications of androgen deprivation therapy for prostate cancer. Saylor PJ; Smith MR J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628 [TBL] [Abstract][Full Text] [Related]
15. Complications of androgen deprivation therapy in prostate cancer. Schwandt A; Garcia JA Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067 [TBL] [Abstract][Full Text] [Related]
17. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Conteduca V; Di Lorenzo G; Tartarone A; Aieta M Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636 [TBL] [Abstract][Full Text] [Related]
18. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. Gomella LG BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166 [TBL] [Abstract][Full Text] [Related]
19. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy. Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568 [TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Singer EA; Golijanin DJ; Messing EM Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]